Remedy Meds vs ShedRx: November 2026 prices compared
As of November 20, 2026, from each program’s own page: on compounded tirzepatide, only Remedy Meds prints a comparable month-to-month price, $399 per 28-day cycle; ShedRx shows only a starting-dose or coupon figure (from $239, "starting as low as"), so no like-for-like comparison is possible.
Released · Last reviewed · how we verify
On compounded semaglutide, only Remedy Meds prints a comparable month-to-month price, $299 per 28-day cycle; ShedRx shows only a starting-dose or coupon figure (from $159, "GLP-1s from $159/mo" (drug not named)), so no like-for-like comparison is possible.
Remedy Meds and ShedRx, measure by measure
| Measure | Remedy Meds | ShedRx |
|---|---|---|
| Tirzepatide, month to month | $399 (per 28-day cycle) | from $239 (lowest printed: "starting as low as"; no month-to-month figure) |
| Tirzepatide, lowest printed | $399 (4-week supply; $279 first month only) | $239 ("starting as low as") |
| Semaglutide, month to month | $299 (per 28-day cycle) | from $159 (lowest printed: "GLP-1s from $159/mo" (drug not named); no month-to-month figure) |
| Semaglutide, lowest printed | $299 (4-week supply; $179 first month only) | $159 ("GLP-1s from $159/mo" (drug not named)) |
| Dose pricing | same price at every dose | priced by dose or not stated |
| Membership or program fee | none | none |
| Computed score | 24.3 of 40 (position 7 of 27) | 12 of 40 (position 16 of 27) |
| FDA warning letters | 716830 (2025-09-09) | none listed |
| November 20 read | first-party read | first-party read |
Strengths and limitations: which fits whom
Remedy Meds prints one price at every dose with no membership, so a dose increase does not change the bill. ShedRx prints a month-to-month price; confirm whether it changes with the dose before you rely on it for a year. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy; a licensed clinician decides whether either is appropriate for you.
What changed since August
The first version of this comparison used captures from August 5–10, 2026. The November 20 re-read replaces them; the August figures are kept below as history, dated.
| Program | Medication | August 5–10, 2026 | November 20, 2026 |
|---|---|---|---|
| Remedy Meds | tirzepatide | — | $399 |
| Remedy Meds | semaglutide | — | $299 |
| ShedRx | tirzepatide | — | from $239 |
| ShedRx | semaglutide | — | from $159 |
Regulatory record
FDA’s warning-letter index lists warning letter 716830 (dated September 9, 2025, subject “Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)”) to Remedy Meds; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.
Frequently asked
Which is cheaper, Remedy Meds or ShedRx?
On compounded tirzepatide, only Remedy Meds prints a comparable month-to-month price, $399 per 28-day cycle; ShedRx shows only a starting-dose or coupon figure (from $239, "starting as low as"), so no like-for-like comparison is possible. On compounded semaglutide, only Remedy Meds prints a comparable month-to-month price, $299 per 28-day cycle; ShedRx shows only a starting-dose or coupon figure (from $159, "GLP-1s from $159/mo" (drug not named)), so no like-for-like comparison is possible.
Do Remedy Meds and ShedRx charge a membership fee?
Remedy Meds: no membership fee; ShedRx: no membership fee. This site folds any required recurring fee into the all-in figures above, so the comparison already counts it.
Are Remedy Meds and ShedRx medications FDA-approved?
Compounded tirzepatide and semaglutide from any telehealth program are not FDA-approved and are not the same products as Zepbound, Mounjaro, Wegovy or Ozempic. Brand medications sold through a manufacturer or a brand route are FDA-approved. Ask each program which pharmacy fills the prescription.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- Remedy Meds pricing page (read November 20, 2026)
- ShedRx pricing page (read November 20, 2026)
- FDA warning letter 716830 to Remedy Meds (dated 2025-09-09, posted 2025-09-16)